At present, it is usually used to activate T cells and redirect them to specific target cells. In addition, it refers to the polynucleotide encoding the binding molecule as a Gemini antigen, as well as the carrier and the host cell including the polynucleotide. It also involves the production of conjugated molecules to the current biscience antigens,And the use of these twin antigen binding molecules to treat diseases. 1. Claim 1: a T-type two activated antigen binding molecules, including (a) other antigens specifically combined with the first antigen； (b) other antigens specifically combined with the second antigen； the first antigen is cell antigen The second antigen is Step-1, or the first one is Step-1, and the second one is the antigen of T-type activated cells；and wherein the antigen-binding moiety that specifically binds STEAP-1 comprises a heavy chain variable region, particularly a humanized heavy chain variable region, which comprises the determining region of the heavy chain complementarity (HCDR) 1 of SEQ ID No. 14, HCDR 2 of SEQ ID No. 15 and HCDR 3 of SEQ ID No. 16, and a variable light chain region, particularly a humanized light chain variable region, comprising the determining region of light chain complementarity (LCDR) 1 of SEQ ID No. 17, LCDR 2 of SEQ ID No. 18 and LCDR 3 of SEQ ID No. 19.La presente se refiere generalmente a moléculas de unión a antígeno biespecíficas para la activación de células T y su redireccionamiento a células diana específicas. Además, se refiere a polinucleótidos que codifican dichas moléculas de unión a antígeno biespecíficas, y a vectores y células hospedadoras que comprenden dichos polinucleótidos. Se refiere además a métodos para producir las moléculas de unión a antígeno biespecíficas de la presente, y a métodos para usar estas moléculas de unión antígeno biespecíficas en el tratamiento de enfermedades. Reivindicación 1: Una molécula de unión a antígeno biespecífica activadora de células T que comprende (a) un prim
